Developments in nanomedicine are expected to provide solutions to many of modern medicine's unsolved problems, so it is no surprise that the literature contains many articles discussing the subject. However, existing reviews tend to focus on specific sectors of nanomedicine or to take a very forward-looking stance and fail to provide a complete perspective on the current landscape. This article provides a more comprehensive and contemporary inventory of nanomedicine products. A keyword search of literature, clinical trial registries, and the Web yielded 247 nanomedicine products that are approved or in various stages of clinical study. Specific information on each was gathered, so the overall field could be described based on various dimensions, including FDA classification, approval status, nanoscale size, treated condition, nanostructure, and others. In addition to documenting the many nanomedicine products already in use in humans, this study indentifies several interesting trends forecasting the future of nanomedicine.
Nanotechnology will significantly benefit society, producing major advances in energy, including economic solar cells 1 and high-performance batteries 2 ; electronics, with ultrahigh density data storage 3 and single-atom transistors 4 ; and food and agriculture, offering smart delivery of nutrients and increased screening for contaminants. 5 However, two of the most exciting and promising domains for advancement are health and medicine. Nanotechnology offers potential developments in pharmaceuticals, 6 medical imaging and diagnosis, 7, 8 cancer treatment, 9 implantable materials, 10 tissue regeneration, 11 and even multifunctional platforms combining several of these modes of action into packages a fraction the size of a cell. 12, 13 Although there have been articles describing the expected benefits of nanotechnology in medicine, there has been less effort placed on providing a comprehensive picture of its current status and how this will guide the future trajectory. Wagner et al summarized the findings of a 2005 study commissioned by the European Science and Technology Observatory (ETSO), 14, 15 including a list of approved products and data on developing applications and the companies involved, but with emphasis more on the economic potential than on trends in the technology. A number of articles have analyzed specific sectors of nanomedicine, including liposomes 16, 17 nanoparticles (NPs) for drug delivery, 18, 19 emulsions, 20 imaging, 21 biomaterials, 22, 23 and in vitro diagnostics, 24 but such focused discussions do not provide insight into the overall trajectory of nanomaterials in medicine.
Industry market reports describing companies and their products related to nanomedicine and nanobiotechnology have also begun to emerge in the last several years, 25, 26 but this information is difficult to access for the average researcher or engineer, due to the high subscription costs. The objective of this review is then to fill an important gap in literature by analyzing the current nanomedicine landscape (commercialized and investigational nanomedicine products) on a number of important dimensions to identify the emerging trends. This original approach provides a solid groundwork for anticipating the next phases of nanomedicine development, highlighting valuable perspectives relevant to the field.
Scope of analysis
The definitions of "nanotechnology" and "nanomedicine" continue to be an area of controversy, with no universally accepted classification. Because an operational definition is required for the purposes of this study, nanomedicine is taken as the use of nanoscale or nanostructured materials in medicine, engineered to have unique medical effects based on their structures, including structures with at least one characteristic dimension up to 300 nm. Nanomedicine takes advantage of two general phenomena that occur at the nanoscale: transitions in physiochemical properties and transitions in physiological interactions. Many of the early definitions of nanotechnology employ a cut-off around 100 nm (including that of the National Nanotechnology Initiative (NNI), 27 focusing on the former, where quantum effects are often restricted to structures on the order of ones to tens of nanometers. 28, 29 However, unique physiochemical behavior sometimes emerges for nanomaterials with defining features greater than 100 nm (e.g., the plasmon-resonance in 150 nm diameter gold nanoshells that are currently under clinical investigation for cancer thermal therapy 30 ). In addition, many of the benefits (and risks) of nanomedicine are related to the unique physiological interactions that appear in the transition between the molecular and microscopic scales. At the systemic level, drug bioavailability is increased due to the high relative surface area of NPs, 31 and it has been shown that liposomes around 150 nm to 200 nm in diameter remain in the bloodstream longer than those with diameters less than 70 nm. 32 At the tissue level, many nanomedicine products attempt to passively target sites through the enhanced permeability and retention (EPR) effect, with feature sizes typically in the 100 nm to 200 nm range, but particles up to 400 nm have demonstrated extravasation and accumulation in tumors 33 (although this is an extreme case). At the cellular level, NP uptake and processing pathways depend on many properties, 34 but size is a critical factor. Although optimal cellular uptake for colloidal gold has been shown for sizes of around 50 nm, 35 macrophages can easily phagocytose polystyrene beads up to 200 nm in diameter. 36 So, although much of nanomedicine utilizes feature sizes at or below 100 nm, this cut-off excludes many applications with significant consequence to the field. Thus we chose 300 nm to better encompass the unique physiological behavior that is occurring on these scales. It should also be noted that all this behavior is highly material-and geometry-specific, with much of the previous discussion focusing on spherical NPs, as they are the most prominent in literature. However, many newly developing particles utilize high aspect ratios or nanoscale features on microscale platforms to enhance vascular extravasation 37 and this will still fall under the purview of our definition.
An application will generally move through five developmental phases, from basic science to a commercialized medical product ( Figure 1 ). To depict and analyze the nanomedicine landscape, we focused on identifying applications that are undergoing or on the verge of clinical investigation in human participants, as well as products already approved by the U.S. Food and Drug Administration (FDA) or foreign equivalent. This excludes applications that are earlier in the pipeline, such as those in bench science or early animal testing. Many of the revolutionary nanomedicine technologies anticipated in the literature may be 20 or more years from clinical use. It is difficult to speculate about the forms in which these may finally be implemented and the ultimate impact they may have. For instance, in a 2006 survey, academic, government, and industry experts did not expect to see "nanomachines" capable of theranostics (combined therapy and diagnostics) in human beings until 2025. 38 Our study thus focuses on applications and products that are already being tested or used in humans. These applications and products will have the most significant impact on industry, regulation, and society for the foreseeable future.
Methods
We used a structured sequence of Internet searches to identify nanomedicine applications and products. Targeted searches on PubMed.gov, Google, and Google Scholar, and a number of clinical trial registries produced a range of resources, including journal articles, consumer websites, commercial websites, clinical trial summaries, manufacturer documents, conference proceedings, and patents. All of those were used to identify potential nanomedicine applications and products. Information was gathered on each of the identified applications and products through additional searches, and the results were recorded and sorted in several Microsoft Excel databases. All searches were performed by Michael Etheridge under the supervision of Jeff McCullough (Co-Investigator), with input and feedback from Susan Wolf (Principal Investigator) and the full project working group funded by a grant from the National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI) (#1-RC1-HG005338-01). Although these research methods used a broad range of keywords to conduct the most comprehensive search possible, product literature without mention of nanorelated terminology will not be identified through this approach.
To offer a more detailed description of the search methodology and classification process, initial searches were conducted through Web-based search engines including PubMed.gov, Google, and Google Scholar. The initial searches and filtering were conducted in January through March of 2010, then rerun in May of 2011 to capture any new material published in the interim. The search terms used were: "nanomedicine AND product(s)," "nanomedicine AND commercial," "nanobiotechnology AND product(s)," "nanobiotechnology AND commercial," "nanotechnology AND product(s)," "nanotechnology AND commercial," "nano AND product(s)," and "nano AND commercial." We filtered the results to capture lists, tables, and databases cataloging nanotechnology applications and products related to medicine (generally identified as "nanomedicine," "nanobiotechnology," or "medical nanotechnology"). These lists, tables, and databases appeared in review articles that detailed applications in a specific sector of nanomedicine and public service websites that cataloged nanotechnology products for consumer awareness (such as The Project for Emerging Nanotechnologies 39 ). No significant filtering of the applications and products themselves was performed at this point; all applications and products identified as nanotechnology related to medicine were recorded for further analysis.
We conducted additional searches through Web-based clinical trial registries. ClinicalTrials.gov was the main focus of our research efforts, but the results were supplemented with reviews of: Table 1 ). The search terms fell into two categories: general nano terminology (nano, nanotechnology, etc.) and specific nanotechnology platforms (NP, liposome, emulsion, etc.). The keyword searches resulted in identification of over 1,000 distinct clinical trials, which were then reviewed for relevance to nanomedicine. Any information provided (such as sponsor, product name, published literature, etc.), was used to conduct follow-up, Web-based searches (through Google and Google Scholar) to identify the nanomedicine application or product involved.
Applications and products identified through the above searches were then subjected to an additional round of Webbased searches to add to the information on each application or product. We reviewed manufacturer websites for product information and additional nanomedicine products in their developmental pipeline. We searched Google Scholar for literature containing technical product details. We consulted FDA.gov for approval status, date, and application number. Additional searches were conducted through Google if more information was still needed. We created a database containing the following information (where available/applicable) for each application or product: product name, sponsoring company/ institution, FDA classification, treated condition or device application, delivered therapeutic, nanocomponent, nanoscale dimension, approval status, FDA approval date and application number (for approved products), delivery route, and a short application or product description. Each application or product was then classified using the following five graduated categories, to describe the likelihood that the application or product involved nanomedicine (per our definition): Confirmed -a medical application or product with literature reference citing a functional component with dimension at or less than 300 nm (i.e., "nanoscale"). Likely -a medical application or product with literature reference suggesting a functional component on the nanoscale (e.g., literature notes that product takes advantage of EPR effect), but specific size information was not available. Potential -medical application or product with a functional component that could be on the nanoscale (e.g., liposomes), but without literature reference providing a strong indication of size. Unlikely -medical application or product with literature reference suggesting potential nanocomponent larger than nanoscale (e.g., multilaminar liposomes), but without specific size information. Questionable -applications and products identified in literature as "nanomedicine" or "nanotechnology," but without any clear medical relevance or with a size clearly larger than nanoscale.
Results
The targeted search of clinical trial registries yielded 1,265 potentially relevant clinical trial results. Duplicate results and trials involving clearly non-nano applications or products were eliminated, leaving 789 clinical trials with potential nanomedicine applications or products. The application/product name and company was identified for each of these trials, yielding a total of 141 unique applications and products (many were associated with multiple trials). Thirty-eight of these were already approved products, being investigated for new conditions or being used as active comparators for new products, and the other 103 were new investigational products. The products identified through the clinical trial search were combined with 222 unique applications and products identified through the literature search, resulting in a total of 363 potential nanomedicine applications and products that were the basis for subsequent analyses. This population was then evaluated on various criteria in an attempt to identify representative trends. A complete listing of these results is included in the Supplementary Material available online at http:// www.nanomedjournal.com.
Relevance to nanomedicine and developmental phase Table 2 provides a breakdown of the numbers of applications and products analyzed by their assigned relevance to nanomedicine and investigational phase. Investigational products that were under study for multiple uses are classified based on their latest phase of development. Applications in Phase 0 and Phase IV trials are classified as preclinical and commercial, respectively. A majority of the applications and products identified did demonstrate a high relevance to the nanomedicine definition used; 247 (or 68%) of the applications and products fell into the confirmed or likely categories. Much of the remaining analysis will focus on this subset, because the other applications and products did not demonstrate clear-cut relevance to nanomedicine. In terms of developmental phase, we found a significant number of commercially available products (100 confirmed and likely) and identified a notable drop-off in the number of products beyond Phase II development.
Year of approval
Our analysis of the year of approval includes only confirmed and likely products that were submitted to the FDA regulatory approval process in the U.S. or a foreign approval process outside the U.S. (i.e., this does not include research-use-only and exempt products) ( Figure 2 ). The analysis uses the FDA approval year if the product is U.S. approved or an equivalent foreign approval year if it is not approved within the U.S. Products with an unknown approval date include foreign products for which a date is not readily available. Most of the products approved before the year 2000 were therapeutics, rather than devices. However, in the last decade, approval for therapeutics appears to have remained fairly steady, whereas there is a marked increase in the number of medical devices. Figure 3 shows the mean size of the nanocomponents incorporated in all applications and products for which the information was available. It should be noted that this includes any size information that was available, so the data compare measurements made using a variety of techniques (and in some cases, size data were listed without referencing the measurement technique used). Most applications and products utilize nanocomponents with features at or below 200 nm. The peak at 2000 nm includes a number of products utilizing "nanocrystal" dispersion technology, in which drug particulate is milled down to increase bioavailability, but the resulting size distribution ranges from tens of nanometers up to 2 microns. 40 FDA intervention type 41 Of the confirmed and likely nanomedicine products approved for commercial use, seven fall under the FDA classification for biologicals, 38 for devices, and 32 for drugs (Table 3) . Of those applications in clinical study, 26 are biologicals, 21 are devices, Type of nanostructure Table 4 provides a breakdown of the type of nanostructures utilized in the confirmed and likely nanomedicine products. The various forms of free NPs were the most prevalent categories, with significant numbers in both commercial products and investigational applications. However, NPs can also be incorporated into nanocomposites and coatings, and these were classified separately. The high level of development in nanoscale liposomes and emulsions should be highlighted; many developing drug-delivery platforms take advantage of liposomal and emulsion formulations.
Size of nanocomponents

Applications for therapeutics
"Therapeutics" were generally defined to include drugs, vaccines, and biologicals that are intended to directly remedy a medical condition. The uses for each of the confirmed and likely therapeutic products were grouped into nine categories based on the approved or intended use: cancer treatment, hepatitis, (other) infectious diseases, anesthetics, cardiac/vascular disorders, inflammatory/immune disorders, endocrine/exocrine disorders, degenerative disorders, and others ( Figure 4 ). The number of approved products is similar across all the categories. However, about two-thirds of the investigational applications identified are focused on cancer treatment.
Applications for medical devices
All other applications and products were generally classified as devices and a similar categorization approach was used ( Figure 4) . The device categories included in vitro testing, in vivo imaging, in vivo device coatings, bone substitutes, dental, medical dressings/textiles, cancer treatment, surgical devices, Confirmed  14  29  8  32  3  7  93  54  Likely  18  18  2  10  0  6  54  46  Potential  10  9  1  3  0  3  26  18  Unlikely  1  3  1  2  0  3  10  7  Questionable  3  9  1  2  1  0  16  24  Terminated /Discontinued  1  4  0  5  0  4  14  1  Totals  47  72  13  54  4 drug delivery, tissue engineering, and other. In vitro testing and in vivo imaging were the most prominent categories, followed by in vivo device coatings and bone substitutes. It should also be noted that many fewer investigational devices were found than investigational therapeutics. This may be due to the differences in the nature of the approval processes between drugs and devices; clinical drug data are generated more often than data for devices, which are often approved through alternative approval paths (e.g., the 510(k) pathway).
Administration and targeting
One of the key benefits offered by nanoscale structures in medicine is the ability to achieve unique biodistribution profiles that are not possible with purely molecular or microscale delivery, and well-designed nanosystems offer the possibility to preferentially target specific tissues. One of the important factors in determining the resulting biodistribution profile is the route of administration. The confirmed and likely applications and products identified demonstrated a heavy focus on intravenous (IV) administration ( Figure 5 ). Over 120 (or 73%) of the directly administered applications and products were intended for IV use. Another 15 were intended for topical administration. The remaining products were relatively evenly distributed among intramuscular, subcutaneous, and interstitial injection and oral, aerosol, nasal, and ophthalmic ingestion.
Once a product is administered into the body, the nanoplatform design can take advantage of various mechanisms to affect the subsequent biodistribution and preferentially target a specific tissue. However, the sophistication of targeting varies. As discussed earlier, many delivery platforms are attempting to take advantage of the EPR effect, and this purely size-and geometrydependent mode of action is generally termed "passive targeting." However, "active targeting" is another term used frequently in literature and, for the purposes of this study, it is defined as utilizing a mechanism beyond size-dependent biodistribution to enhance preferential delivery to a specific tissue.
Further expanding the analysis in Figure 5 , 17 of the approved products utilized passive targeting and only one took advantage of active targeting. However, 69 products under clinical study capitalize on passive targeting, and another 19 exploit active targeting. All of the actively targeted products are aimed at diagnosing or treating various forms of cancer (Table 5 ). The dominant targeting mechanism is functionalizing the NP with ligands (transferrin, antibodies, etc.) for receptors that are overexpressed in the cancer cells or matrix. However, two products take a unique approach, limiting therapeutic activation until the target tissue is reached. Opaxio™ is a polymeric NP that delivers a form of Paclitaxel and is only activated once enzyme activity specific to the tumor site cleaves the therapeutic molecule. 42 ThermoDox® utilizes a thermosensitive lipid, which will only deliver the Doxorubicin payload when an external heat source is applied. This heat source can be limited to the target site, releasing the drug from the liposomes that were passively delivered. 43 A drug emulsion that does not strictly fit the definition of active targeting is also listed but is notable as the only application identified that claims the ability to cross the blood-brain-barrier and thus demonstrates a higher level of targeting than the other passive modes of delivery. 44 
Nanomedicine companies
We found that a total of 241 companies and institutions (universities and medical centers) were associated with the initial 363 products identified. In addition, 169 companies and institutions were associated with the confirmed or likely nanomedicine applications and products, with 54 of these companies and institutions developing more than one application or product (ranging between two and ten). This means that over one-third of the development in the field is occurring at companies and institutions with only one nanotechnologybased application or product. It should also be noted that this only includes companies and institutions directly responsible for developing the nanomedicine applications and products. Other reviews and market reports cite larger numbers of "nanomedicine companies," but these lists often include firms that are investing heavily in nanomedicine development, companies with processes or technology enabling nanomedicine production, and companies developing applications with unrealized or longterm potential in nanomedicine.
Discussion
This study identified a significant number of nanomedicine products approved for or nearing in-human use. It is difficult to extrapolate these numbers directly, because growth in medical industries is so heavily influenced by swings in the economy and regulatory processes. However, we observed some definite trends related to the future of nanomedicine. The most prominent theme throughout is the relative adolescence of the field. Although all the applications identified represent significant technological advancements, they are only scratching the surface of the potential available, and the continued refinement and combination of these technologies will lead to the truly transformative capabilities envisioned for nanomedicine.
One of the major observations in conducting this study is the difficulty in locating basic information on nanomedicine products. This is partly due to the lack of a clear definition and categorization of nanomedicine as a unique product class. However, it is also difficult to identify products that do not use nano-related terminology in their literature, and this can serve as an impetus for companies to avoid nano branding, if they perceive an elevated regulatory effort or negative public perception. This highlights two clear consequences. First, a larger effort, beyond literature-based examination, is required to make an all-inclusive survey of the field. Secondly, such an effort needs to be conducted in a manner that addresses current barriers to nanomedicine development, rather than introducing new ones. However, some progress is being made in this direction, where the National Cancer Institute (NCI) and FDA are leading efforts to standardize characterization of nanomaterials and information collection on nanomedicine products. NCI established the Nanotechnology Characterization Lab (NCL), which developed a "standardized analytical cascade that tests the preclinical toxicology, pharmacology, and efficacy of nanoparticles and devices." 66 These tests provide physiochemical, in vitro, and in vivo characterization of nanoplatforms, supplying results in a standard report format, in an attempt to better prepare products for the clinical approval process. The NCL has characterized over 200 nanomaterials from academia, government, and industry using their standardized protocols. 67 In addition, the FDA Office of Pharmaceuticals Science (OPS) recently released a Manual of Policies and Procedures (MAPP 5015.9) document instructing reviewers on gathering information on nanomaterial size, functionality, and other characteristics for use in a developing database. The document also includes a more inclusive definition of "nanoscale" and "nanomedicine" that encompasses any material with at least one dimension smaller than 1000 nm, 68 which is intended as a broad net to capture all relevant information in these early stages. These steps demonstrate the type of standardization and information sharing that will be necessary to facilitate coordination in this developing field.
The most overwhelming trend observed in the data is the many cancer treatments under development. This circumstance can be tied to the significant investments NCI has made in nanotechnology over the past decade, 69 the fact that cancer is the worldwide leading cause of death, 70 and the inherent benefits that nanoplatforms offer for therapeutic delivery. However, it might also be due in part to the sense that life-threatening cancers warrant the investigation of treatments using emerging technologies such as nanotechnology. Forty-seven percent of all the confirmed and likely in vivo products were intended for acutely life-threatening conditions (mostly advanced cancers). Some uncertainty about risks, especially longer-term risks, may be more tolerable in such cases.
The majority of the cancer treatment applications identified in this study were aimed at increasing the efficacy of therapeutic delivery, but the envisioned impact of nanotechnology in cancer medicine is much more transformative, including the advent of personalized medicine and point-of-care diagnostics. The keys to this field are adequate identification and understanding of the biomarkers involved in different disease states. Important developments in nanotechnology over the last decade have provided the tools necessary to probe this understanding, 71 while also providing the platforms to implement the improved diagnostics and therapies applying this knowledge. This synergistic role of nanotechnology as both driver and vehicle has allowed the field to reach a tipping point where accelerated growth is likely.
Another theme playing a major role in today's nanomedicine that is likely to undergo significant development in the near future is in vivo targeting. A large number of products utilizing the EPR effect were identified, as well as several taking advantage of more active modes of targeting. The value of targeting in nanomedicine has certainly been acknowledged, but there is still much debate around the role and importance of different factors. Much work is still needed to characterize the full impact of size, shape, surface chemistry, delivery method, the EPR effect, biomolecular targeting, characteristics of polyethylene glycol (PEG)-coatings, formation of the protein corona, and intracellular targeting, before maximally effective delivery can be realized, 59, 72, 73 but this is and will continue to be a major focus in nanomedicine.
One of the major concerns regarding the use of nanotechnology in the body is the question of persistence. Traditional molecular therapeutics are generally processed by the body and the metabolites are excreted soon after administration, but some NPs have demonstrated persistent in vivo deposits for months or years. 74, 75 Examination of the in vivo applications and products identified demonstrates a much higher prevalence of "soft" (157 applications and products) versus "hard" (30 applications and products) nanostructures. The hard NPs identified generally consist of iron oxide, gold, silver, or ceramic, but several applications nearing clinical study plan to use carbon 76 or hafnium oxide 77 NPs. "Soft" is a term generally used in contrast to hard material NPs 78 and here is taken to include liposomes, micelles, emulsions, dendrimers, and other polymeric and protein nanostructures. Iron oxide particles are used in MR contrast 79, 80 and cancer thermal therapies. 75, 81 Colloidal gold is being used in systemic delivery of therapeutic biologicals 82 and for cancer thermal therapies. 83 Nanosilver is being used in antimicrobial coatings for several implanted devices and catheters. 22, 84, 85 Ceramic NPs are used as strength and optical enhancers in a number of dental composites. 86 Although all these materials have demonstrated biocompatibility through current standards, there is some question whether persistence in the body may produce longer-term toxicities not seen with current medicines and treatments. A notable number of boneimplant applications also utilized hydroxyapatite 14, 62, 77, 87, 88 or calcium phosphate 62,89 nanocrystals (13 applications and products), but these were not included in the hard NP count because these forms naturally occur in the body. 77 It is likely that both hard and soft NPs will find established roles in the future of nanomedicine. Biodegradable platforms will likely be preferred for therapeutic delivery applications, but most of the unique physiochemical behavior arises only in metallic or semiconductor NPs, so these will be required for future imaging and electromagnetic-wave-based therapies. Nanomaterials for tissue regeneration are an additional highly touted area of development in nanomedicine. 71 However, this study was only able to identify two applications related to tissue regeneration. Both were implantable softtissue scaffolds with nanostructured surfaces. 39, 90 It is likely that nanomaterials will be critical in developing the surfaces and structures required for ex vivo tissue growth and implantation of engineering tissues, but a better understanding of the adequate conditions and biological signals to trigger growth and proliferation is necessary, before these materials can be properly designed.
As noted in Table 2 , fifteen products were identified that were discontinued after approval or during clinical investigation. However, the literature showed no clear reason in common among these cases. One nanocrystal drug formulation was discontinued after being on the market since the 1980s, 91 but there was no indication that this was due to post-market safety concerns; this formulation was most likely displaced by newer products. Reasons for terminating clinical investigation were fairly evenly distributed among lack of efficacy, systemic toxicity, low enrollment, and licensing or funding issues. However, we found no explanation for terminating study in three cases. In addition, a number of other applications and products were associated with clinical trials that had been terminated, but development continued with adjusted drug formulations or for other indications.
The clinical approval process is structured to ensure that sponsors demonstrate adequate safety and efficacy before a product is released to market. However, the 510(k) device approval process has recently come under fire as a potential pathway for allowing unsatisfactory products to market. 92 Our study identified a significant number of nanomedicine products that were approved through the 510(k) process (Table 6) , falling into general categories of bone substitutes, dental composites, device coatings, in vitro assays, medical dressings, dialysis filters, and tissue scaffolds. Many of these products have been in use for a number of years without issue. This suggests that safety concerns about the 510(k) process have not been borne out to date by nanomedicine products. That said, information may become available in the future on potential toxicological risks associated with the use of in vivo nanomaterials, and that points to the importance of clearly identifying products that incorporate some form of nanotechnology so they can be adequately tracked.
Much of the forecasted promise of nanotechnology in medicine takes the form of smart technologies, such as theranostic platforms that can target, diagnose, and administer appropriate treatment to different disease states in the body. However, the current study shows that nanomedicine is still in an early state. As with any emerging field of science, progress is made in steps and some developing applications are just beginning to demonstrate higher levels of sophistication. Active forms of targeting have already been discussed, but active nanomedicine can be more generally defined as nanostructures that induce a mechanism of action beyond purely size-dependent biological and chemical interactions. Table 7 lists the additional active applications and products identified (beyond active targeting) and several of the areas are discussed in more detail below. Several forms of electromagnetically activated NPs intended for cancer treatment are currently nearing or progressing through clinical development. NanoTherm® and Targeted Nano-Therapeutics utilize interstitial or intravenous delivery of iron oxide NPs, which are then heated by an externally applied alternating magnetic field, to provide hyperthermia treatment localized to a tumor. 75, 81 AuroShell® uses intravenously injected gold nanoshells, which are heated by a fiberoptic, infrared laser probe to provide high temperatures localized to the tumor area. 83 An additional preclinical NP platform, NanoXray™, is excited by x-rays, to induce local electron emission in the tumor, leading to free radicals that cause intracellular damage. 77, 114 NPs are also being used to enhance imaging techniques. Five approved applications utilizing iron oxide NPs for in vivo MRI enhancement were identified, with another four under clinical investigation. 79, 80 The iron oxide NPs passively collect in different tissues and provide enhanced contrast due to localized magnetic effects. Six in vitro applications were also identified in which quantum dots with biomolecular tagging are used for fluorescent microscopy. However, uncertainty remains as to whether quantum dots in their current form will ever find in vivo use, due to the potential toxicity associated with the heavy metals used. 115 Two other products were identified in which iron oxide NPs are used for magnetic detection of cells in vitro (CellSearch® and NanoDX™). The magnetic NPs are tagged with cell-specific markers, and an external field is used to separate or aggregate the bound cells in solution, allowing detection. 113, 116 Similar techniques have been used to enhance drug targeting in animal models 117 and have been proposed for detoxifying circulating blood. 118 One Phase I clinical trial attempted to demonstrate the benefits of magnetic drug targeting in humans in the mid-1990s but met with limited efficacy. 119 Some companies are pursuing new methods of magnetically enhanced drug delivery and release but have not yet moved into human trials. 120 The next phases of development in nanomedicine are likely to take advantage of combined applications in the form of both multimodal treatments (utilizing nanomedicine in combination with current treatments) and theranostic platforms (single nanomedicine applications with multiple modes of action). The MagForce NanoTherm®, magnetically heated iron oxide NPs have already demonstrated synergistic effects in combined treatment with chemotherapy and radiotherapy, allowing lower dosages for each. 121 In addition, Cytimmune's TNF-α labeled gold NPs have been shown to effect tissues perfusion and increase sensitivity to thermal therapies, 122 offering potential preconditioning for a number of applications. Gold NPs have also demonstrated the capability to thermally treat tumors under laser excitation 83 and are under preclinical study for disease diagnosis through surface-enhanced Raman spectroscopy. 123 These current technologies could be combined in an endoscopic application for real-time diagnosis and treatment for many gastrointestinal cancers. As the basic capabilities of NPs are established through single modes of action, it is likely that combined nanomedicine treatments will become more prevalent.
Nanomedicine is a very diverse field and that characteristic creates some difficulty in creating clear definitions, as well as effective oversight and regulation. A detailed search of the literature, clinical trial data, and the Web identified 247 applications and products that were confirmed or likely nanomedicine interventions (under our definition) and that were This study reveals two clear needs that should be addressed for any regulatory approach for nanomedicine to succeed: 1) developing an effective and clear definition outlining the field and 2) creating a standardized approach for gathering, sharing, and tracking relevant information on nanomedicine applications and products (without creating additional barriers for medical innovation). Both the NCL and FDA are taking steps in the right direction, but broader-reaching efforts are necessary to clarify the definition of "nanomedicine," track key data, and facilitate coordination among agencies in this complex arena. A categorical analysis of the identified applications and products also provides insight into the future directions of the field. We found a pronounced focus on development of cancer applications. This is likely a result of several factors, including heavy investments made by NCI, the prevalence and impact of cancer in society, and the reality that the risks of many nanomedicine trials may be offset by the benefit sought in treating life-threatening cancers.
Finally, although nanomedicine has already established a substantial presence in today's markets, this analysis also highlights the infancy of the field. This is not to downplay the advances made to date; engineered nanoscale materials have already provided medical enhancements that are not possible on the molecular or micro scale. However, a large portion of the nanomedicine applications identified are still in the research and development stage. Continued development and combination of these applications should lead to the truly revolutionary advances foreseen in medicine. Now is the time to put in place effective data-gathering strategies and analytical approaches that will advance understanding of this field's evolution and help to optimize development of nanomedicine and assure sound approaches to oversight.
